EGFR and bone metastasis: Previous EGFR TKI treatment was associated with a lower risk of ADRs, whereas ECOG PS 2–4, female gender, bone metastasis, and previous and concomitant gastrointestinal disorders were all associated with a significantly higher risk of grade ≥ 3 ADRs.